The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update

The 2024 updates of the Chinese Society of Clinical Oncology (CSCO) Clinical Guidelines for the diagnosis and treatment of colorectal cancer emphasize standardizing cancer treatment in China, highlighting the latest advancements in evidence-based medicine, healthcare resource access, and precision medicine in oncology. These updates address disparities in epidemiological trends, clinicopathological characteristics, tumor biology, treatment approaches, and drug selection for colorectal cancer patients across diverse regions and backgrounds. Key revisions include adjustments to evidence levels for intensive treatment strategies, updates to regimens for deficient mismatch repair (dMMR)/ microsatellite instability-high (MSI-H) patients, proficient mismatch repair (pMMR)/ microsatellite stability (MSS) patients who have failed standard therapies, and rectal cancer patients with low recurrence risk. Additionally, recommendations for digital rectal examination and DNA polymerase epsilon (POLE)/ DNA polymerase delta 1 (POLD1) gene mutation testing have been strengthened. The 2024 CSCO Guidelines are based on both Chinese and international clinical research, as well as expert consensus, ensuring their relevance and applicability in clinical practice, while maintaining a commitment to scientific rigor, impartiality, and timely updates.

Authors

Institutions

Publication Details

Journal
Cancer Communications
Published
2024-12-31
DOI
https://doi.org/10.1002/cac2.12639
Citations
42
Primary Topic
Colorectal Cancer Surgical Treatments
Type
article
Field-Weighted Citation Impact
11.58
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update

Jianming Ying, Liuhong Wang, Muyan Cai, Hanguang Hu et al.
42 citations
Cancer Communications
Colorectal Cancer Surgical Treatments
11.58
article

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update

Jianming Ying, Liuhong Wang, Muyan Cai, Hanguang Hu, Suzhan Zhang, Xinxiang Li, Guichao Li, Zixian Wang, Weiqi Sheng, Jingyu Wang, Ying Yuan, Taiyuan Li, Feng Wang, Zhen Zhang, Yunpeng Liu, Yuanhong Gao, Jin Li, Gong Chen, Jianmin Xu, Sanjun Cai, Li Ren, Yi Wang, Houjie Liang, Kejun Nan, Rui‐Hua Xu, Xicheng Wang, Gang Ji, Aiping Zhou, Xianglin Yuan, Yanqiao Zhang
article en
42 citations

Abstract

The 2024 updates of the Chinese Society of Clinical Oncology (CSCO) Clinical Guidelines for the diagnosis and treatment of colorectal cancer emphasize standardizing cancer treatment in China, highlighting the latest advancements in evidence-based medicine, healthcare resource access, and precision medicine in oncology. These updates address disparities in epidemiological trends, clinicopathological characteristics, tumor biology, treatment approaches, and drug selection for colorectal cancer patients across diverse regions and backgrounds. Key revisions include adjustments to evidence levels for intensive treatment strategies, updates to regimens for deficient mismatch repair (dMMR)/ microsatellite instability-high (MSI-H) patients, proficient mismatch repair (pMMR)/ microsatellite stability (MSS) patients who have failed standard therapies, and rectal cancer patients with low recurrence risk. Additionally, recommendations for digital rectal examination and DNA polymerase epsilon (POLE)/ DNA polymerase delta 1 (POLD1) gene mutation testing have been strengthened. The 2024 CSCO Guidelines are based on both Chinese and international clinical research, as well as expert consensus, ensuring their relevance and applicability in clinical practice, while maintaining a commitment to scientific rigor, impartiality, and timely updates.

Cancer CommunicationsVol. 45(3)
Academy of Medical Sciences (GB), Southwest General Health Center (US), Nanchang University (CN), Army Medical University (CN), Harbin Medical University (CN), Sun Yat-sen University (CN), China Pharmaceutical University (CN), Jilin University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking University (CN), Fudan University (CN), Peking Union Medical College Hospital (CN), Fudan University Shanghai Cancer Center (CN), Third Affiliated Hospital of Harbin Medical University (CN), Shanghai Cancer Institute (CN), First Affiliated Hospital of Xi'an Jiaotong University (CN), Peking University People's Hospital (CN), First Hospital of Jilin University (CN), Zhongshan Hospital (CN), The First Affiliated Hospital, Sun Yat-sen University (CN), Southwest Hospital (CN), First Hospital of China Medical University (CN), Sun Yat-sen University Cancer Center (CN), Second Affiliated Hospital of Zhejiang University (CN), Xijing Hospital (CN), Tongji Hospital (CN), First Affiliated Hospital of Nanchang University (CN), Huazhong University of Science and Technology (CN), Zhejiang University (CN), China Medical University (CN)
Openalex Percentile: Top 1%
Colorectal Cancer Surgical Treatments
11.58
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.